


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: January 28, 2009

Signature:



(Marshall P. Byrd)

Docket No.: 27373/38819A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bernard Roizman et al.

Application No.: 10/530,774

Confirmation No.: 2653

Filed: November 17, 2005

Art Unit: 1648

For: TARGETING OF HERPES SIMPLEX VIRUS
TO SPECIFIC RECEPTORS

Examiner: M. Mosher

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§1.56, 1.97 and 1.98, the Applicants request that the Patent and Trademark Office consider the document listed on the attached Form PTO/SB/08 during prosecution of this application, and make the document of record to appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 CFR § 1.98(a)(2)(ii), Applicant has not submitted a copy of the U.S. patent application.

In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists. In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" to this invention.

In accordance with 37 CFR § 1.97(e)(2), Applicants assert that no item of information contained in the instant Information Disclosure Statement was cited in a

communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

This Information Disclosure Statement is being submitted after the Notice of Allowance and concurrent with the payment of the issue fee. Therefore, as required by 37 CFR § 1.97(d), a statement in accordance with 37 CFR § 1.97(e)(2) and the fees required under 37 CFR § 1.17(p) are submitted herewith. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 13-2855, under Order No. 27373/38819A.

Dated: January 28, 2009

Respectfully submitted,

By 
Marshall P. Byrd

Registration No.: 62,454
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agent for Applicants